In this white paper, we provide an overview of the most common hematologic malignancies, highlight cutting-edge technologies being used to understand these blood cancers, and apply these insights toward the development of novel therapeutics and diagnostics.
Chimeric Antigen Receptor (CAR) T cell therapies have revolutionized the therapeutic management of hematological malignancies and hold great promise for solid tumors. In this case study, we review the preclinical evaluation of a novel CAR T therapy in our rare non-Hodgkin (NH) Diffuse Large B cell Lymphoma (DLBCL) PDX models.
A better understanding of tumor cell biology and resistance mechanisms in Acute Myeloid Leukemia (AML) may shed light on novel therapeutic targets that improve long-term outcomes. In this study, we performed an exhaustive analysis to include deep tumor phenotyping, drug sensitivity profiling, and comprehensive multi-omic characterization.
The therapeutic potential of bromodomain and extra-terminal motif (BET) inhibitors in hematological cancers has been well established in preclinical and early-stage clinical trials, yet no BET-targeting agent has achieved approval. To add insight into the potential response to mivebresib (ABBV-075), a broad-spectrum BET inhibitor, co-clinical modeling of individual patient biopsies was conducted in the context of a Phase I trial in Acute Myeloid Leukemia (AML).
